Notice of Results and Investor Presentation

Venture Life Group PLC

04 April 2024

 

4 April 2024

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

Notice of Results

and

Investor Presentation via Investor Meet Company

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market confirms that it will release its results for the year ended 31 December 2023 on 9 April 2024.

The Company also announces that Jerry Randall (CEO) and Daniel Wells (CFO) will provide a live presentation relating to the 2023 Full Year Results via Investor Meet Company on 11 Apr 2024, 14:30 BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Venture Life Group plc via:

https://www.investormeetcompany.com/venture-life-group-plc/register-investor

Investors who already follow Venture Life Group plc on the Investor Meet Company platform will automatically be invited.

For further information, please contact:

Venture Life Group PLC		[phone]
Jerry Randall, Chief Executive Officer Daniel Wells, Chief Financial Officer
Cavendish Capital Markets Limited (Nomad and Broker)		[phone]
Stephen Keys/Camilla Hume (Corporate Finance) Michael Johnson (Sales)

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the Balance Active range in the area of women's intimate healthcare, the Earol® product line in ENT care, the Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the UltraDEX and Dentyl oral care product ranges, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

END